Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Natl Cancer Inst. 2011 Aug 17;103(16):1222-6. doi: 10.1093/jnci/djr246. Epub 2011 Jul 15.

Opportunities and challenges in the development of experimental drug combinations for cancer.

Author information

  • 1Global Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.

Abstract

It is becoming increasingly evident that cancers are dependent on a number of altered molecular pathways and can develop diverse mechanisms of resistance to therapy with single agents. Therefore, combination regimens may provide the best hope for effective therapies with durable effects. Despite preclinical data to support this notion, there are many challenges to the development of targeted combinations including scientific, economic, legal, and regulatory barriers. A discussion of these challenges and identification of models and best practices are presented with intent of aiding the research community in addressing real and perceived barriers to the development of combination therapies for cancer.

PMID:
21765011
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk